DDInter1311 DDInter1660
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Norepinephrine {u} (Compound) resembles {v} (Compound) Isoprenaline
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Isoprenaline
Isoprenaline {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Phenylephrine
Phenylephrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lithium carbonate
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lithium carbonate
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Isoprenaline
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine {u} (Compound) resembles {v} (Compound) Phenylephrine
Phenylephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Norepinephrine (Compound) resembles Isoprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Isoprenaline (Compound) and Isoprenaline may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Methyldopa (Compound) and Methyldopa (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Isoprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norepinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide